This article is more than 5 years old. Information may no longer be current.

ThromboGenics reports financial update, Jetrea progression

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics reported a decrease in cash and investments in the first quarter 2015 compared with the fourth quarter 2014, according to a press release.

Cash and investments totaled €121.4 million compared with €127.1 million in the previous quarter.

“ThromboGenics believes that it has the financial resources needed to sustain the commercialization of Jetrea in the U.S., to research and develop new indications and formulations of Jetrea for the U.S. market, and to expand its R&D pipeline as it delivers on its commitment to become a leading ophthalmology company,” the release said.

In the U.S., the company is currently commercializing Jetrea (ocriplasmin) for the treatment of vitreomacular adhesion, focusing on key retina accounts, the release said. In Europe, ThromboGenics partnered with Alcon to commercialize Jetrea similar to its U.S. sales strategy.

In addition, the company is assessing Jetrea for the treatment of diabetic retinopathy and retinal vein occlusion.